Skip to main content
Erschienen in: European Radiology 1/2018

28.07.2017 | Neuro

MRI features can predict EGFR expression in lower grade gliomas: A voxel-based radiomic analysis

verfasst von: Yiming Li, Xing Liu, Kaibin Xu, Zenghui Qian, Kai Wang, Xing Fan, Shaowu Li, Yinyan Wang, Tao Jiang

Erschienen in: European Radiology | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Objective

To identify the magnetic resonance imaging (MRI) features associated with epidermal growth factor (EGFR) expression level in lower grade gliomas using radiomic analysis.

Methods

270 lower grade glioma patients with known EGFR expression status were randomly assigned into training (n=200) and validation (n=70) sets, and were subjected to feature extraction. Using a logistic regression model, a signature of MRI features was identified to be predictive of the EGFR expression level in lower grade gliomas in the training set, and the accuracy of prediction was assessed in the validation set.

Results

A signature of 41 MRI features achieved accuracies of 82.5% (area under the curve [AUC] = 0.90) in the training set and 90.0% (AUC = 0.95) in the validation set. This radiomic signature consisted of 25 first-order statistics or related wavelet features (including range, standard deviation, uniformity, variance), one shape and size-based feature (spherical disproportion), and 15 textural features or related wavelet features (including sum variance, sum entropy, run percentage).

Conclusions

A radiomic signature allowing for the prediction of the EGFR expression level in patients with lower grade glioma was identified, suggesting that using tumour-derived radiological features for predicting genomic information is feasible.

Key Points

EGFR expression status is an important biomarker for gliomas.
EGFR in lower grade gliomas could be predicted using radiogenomic analysis.
A logistic regression model is an efficient approach for analysing radiomic features.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Chen B, Liang T, Yang P et al (2016) Classifying lower grade glioma cases according to whole genome gene expression. Oncotarget 7:74031–74042PubMedPubMedCentral Chen B, Liang T, Yang P et al (2016) Classifying lower grade glioma cases according to whole genome gene expression. Oncotarget 7:74031–74042PubMedPubMedCentral
2.
Zurück zum Zitat Fan X, Wang Y, Zhang C et al (2016) ADAM9 Expression Is associate with glioma tumor grade and histological type, and acts as a prognostic factor in lower-grade gliomas. Int J Mol Sci 17 Fan X, Wang Y, Zhang C et al (2016) ADAM9 Expression Is associate with glioma tumor grade and histological type, and acts as a prognostic factor in lower-grade gliomas. Int J Mol Sci 17
3.
Zurück zum Zitat Davis SC, Samkoe KS, O'Hara JA et al (2010) MRI-coupled fluorescence tomography quantifies EGFR activity in brain tumors. Acad Radiol 17:271–276CrossRefPubMedPubMedCentral Davis SC, Samkoe KS, O'Hara JA et al (2010) MRI-coupled fluorescence tomography quantifies EGFR activity in brain tumors. Acad Radiol 17:271–276CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Ramos-Suzarte M, Lorenzo-Luaces P, Lazo NG et al (2012) Treatment of malignant, non-resectable, epithelial origin esophageal tumours with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy. Cancer Biol Ther 13:600–605CrossRefPubMed Ramos-Suzarte M, Lorenzo-Luaces P, Lazo NG et al (2012) Treatment of malignant, non-resectable, epithelial origin esophageal tumours with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy. Cancer Biol Ther 13:600–605CrossRefPubMed
5.
Zurück zum Zitat Reddy BK, Lokesh V, Vidyasagar MS et al (2014) Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open-label, phase IIb, 5-year study in Indian patients. Oral Oncol 50:498–505CrossRefPubMed Reddy BK, Lokesh V, Vidyasagar MS et al (2014) Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open-label, phase IIb, 5-year study in Indian patients. Oral Oncol 50:498–505CrossRefPubMed
6.
Zurück zum Zitat Rodríguez MO, Rivero TC, Del Castillo Bahi R et al (2014) Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck. Cancer Biol Ther 9:343–349CrossRef Rodríguez MO, Rivero TC, Del Castillo Bahi R et al (2014) Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck. Cancer Biol Ther 9:343–349CrossRef
7.
Zurück zum Zitat Basavaraj C, Sierra P, Shivu J, Melarkode R, Monte E, Nair P (2014) Nimotuzumab with chemoradiation confers a survival advantage in treatment-naïve head and neck tumors over expressing EGFR. Cancer Biol Ther 10:673–681CrossRef Basavaraj C, Sierra P, Shivu J, Melarkode R, Monte E, Nair P (2014) Nimotuzumab with chemoradiation confers a survival advantage in treatment-naïve head and neck tumors over expressing EGFR. Cancer Biol Ther 10:673–681CrossRef
8.
Zurück zum Zitat Chong DQ, Toh XY, Ho IA et al (2015) Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status. BMC Cancer 15:255CrossRefPubMedPubMedCentral Chong DQ, Toh XY, Ho IA et al (2015) Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status. BMC Cancer 15:255CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Xu S, Ramos-Suzarte M, Bai X, Xu B (2016) Treatment outcome of nimotuzumab plus chemotherapy in advanced cancer patients: a single institute experience. Oncotarget 7:33391–33407CrossRefPubMedPubMedCentral Xu S, Ramos-Suzarte M, Bai X, Xu B (2016) Treatment outcome of nimotuzumab plus chemotherapy in advanced cancer patients: a single institute experience. Oncotarget 7:33391–33407CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Gupta A, Young RJ, Shah AD et al (2015) Pretreatment Dynamic Susceptibility Contrast MRI Perfusion in Glioblastoma: Prediction of EGFR Gene Amplification. Clin Neuroradiol 25:143–150CrossRefPubMed Gupta A, Young RJ, Shah AD et al (2015) Pretreatment Dynamic Susceptibility Contrast MRI Perfusion in Glioblastoma: Prediction of EGFR Gene Amplification. Clin Neuroradiol 25:143–150CrossRefPubMed
11.
Zurück zum Zitat Yoo RE, Choi SH, Cho HR et al (2013) Tumor blood flow from arterial spin labeling perfusion MRI: a key parameter in distinguishing high-grade gliomas from primary cerebral lymphomas, and in predicting genetic biomarkers in high-grade gliomas. J Magn Reson Imaging 38:852–860CrossRefPubMed Yoo RE, Choi SH, Cho HR et al (2013) Tumor blood flow from arterial spin labeling perfusion MRI: a key parameter in distinguishing high-grade gliomas from primary cerebral lymphomas, and in predicting genetic biomarkers in high-grade gliomas. J Magn Reson Imaging 38:852–860CrossRefPubMed
13.
Zurück zum Zitat Drabycz S, Roldan G, de Robles P et al (2010) An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging. Neuroimage 49:1398–1405CrossRefPubMed Drabycz S, Roldan G, de Robles P et al (2010) An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging. Neuroimage 49:1398–1405CrossRefPubMed
14.
Zurück zum Zitat Korfiatis P, Kline TL, Coufalova L et al (2016) MRI texture features as biomarkers to predict MGMT methylation status in glioblastomas. Med Phys 43:2835CrossRefPubMedPubMedCentral Korfiatis P, Kline TL, Coufalova L et al (2016) MRI texture features as biomarkers to predict MGMT methylation status in glioblastomas. Med Phys 43:2835CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Wang Y, Fan X, Zhang C et al (2014) Identifying radiographic specificity for phosphatase and tensin homolog and epidermal growth factor receptor changes: a quantitative analysis of glioblastomas. Neuroradiology 56:1113–1120CrossRefPubMed Wang Y, Fan X, Zhang C et al (2014) Identifying radiographic specificity for phosphatase and tensin homolog and epidermal growth factor receptor changes: a quantitative analysis of glioblastomas. Neuroradiology 56:1113–1120CrossRefPubMed
16.
Zurück zum Zitat Ricard D, Kaloshi G, Amiel-Benouaich A et al (2007) Dynamic history of low-grade gliomas before and after temozolomide treatment. Ann Neurol 61:484–490CrossRefPubMed Ricard D, Kaloshi G, Amiel-Benouaich A et al (2007) Dynamic history of low-grade gliomas before and after temozolomide treatment. Ann Neurol 61:484–490CrossRefPubMed
17.
Zurück zum Zitat Kinoshita M, Sakai M, Arita H et al (2016) Introduction of High Throughput Magnetic Resonance T2-Weighted Image Texture Analysis for WHO Grade 2 and 3 Gliomas. PLoS One 11, e0164268CrossRefPubMedPubMedCentral Kinoshita M, Sakai M, Arita H et al (2016) Introduction of High Throughput Magnetic Resonance T2-Weighted Image Texture Analysis for WHO Grade 2 and 3 Gliomas. PLoS One 11, e0164268CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Wang Y, Fan X, Li H et al (2015) Tumor border sharpness correlates with HLA-G expression in low-grade gliomas. J Neuroimmunol 282:1–6CrossRefPubMed Wang Y, Fan X, Li H et al (2015) Tumor border sharpness correlates with HLA-G expression in low-grade gliomas. J Neuroimmunol 282:1–6CrossRefPubMed
19.
Zurück zum Zitat Wang YY, Zhang T, Li SW et al (2015) Mapping p53 mutations in low-grade glioma: a voxel-based neuroimaging analysis. AJNR Am J Neuroradiol 36:70–76CrossRefPubMed Wang YY, Zhang T, Li SW et al (2015) Mapping p53 mutations in low-grade glioma: a voxel-based neuroimaging analysis. AJNR Am J Neuroradiol 36:70–76CrossRefPubMed
20.
Zurück zum Zitat Aerts HJ, Velazquez ER, Leijenaar RT et al (2014) Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun 5:4006PubMedPubMedCentral Aerts HJ, Velazquez ER, Leijenaar RT et al (2014) Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun 5:4006PubMedPubMedCentral
21.
Zurück zum Zitat Herold CJ, Lewin JS, Wibmer AG et al (2016) Imaging in the Age of Precision Medicine: Summary of the Proceedings of the 10th Biannual Symposium of the International Society for Strategic Studies in Radiology. Radiology 279:226–238CrossRefPubMed Herold CJ, Lewin JS, Wibmer AG et al (2016) Imaging in the Age of Precision Medicine: Summary of the Proceedings of the 10th Biannual Symposium of the International Society for Strategic Studies in Radiology. Radiology 279:226–238CrossRefPubMed
22.
Zurück zum Zitat Kickingereder P, Burth S, Wick A et al (2016) Radiomic Profiling of Glioblastoma: Identifying an Imaging Predictor of Patient Survival with Improved Performance over Established Clinical and Radiologic Risk Models. Radiology 280:880–889CrossRefPubMed Kickingereder P, Burth S, Wick A et al (2016) Radiomic Profiling of Glioblastoma: Identifying an Imaging Predictor of Patient Survival with Improved Performance over Established Clinical and Radiologic Risk Models. Radiology 280:880–889CrossRefPubMed
24.
Zurück zum Zitat Segal E, Sirlin CB, Ooi C et al (2007) Decoding global gene expression programs in liver cancer by noninvasive imaging. Nat Biotechnol 25:675–680CrossRefPubMed Segal E, Sirlin CB, Ooi C et al (2007) Decoding global gene expression programs in liver cancer by noninvasive imaging. Nat Biotechnol 25:675–680CrossRefPubMed
25.
Zurück zum Zitat Qiao XJ, Ellingson BM, Kim HJ et al (2015) Arterial spin-labeling perfusion MRI stratifies progression-free survival and correlates with epidermal growth factor receptor status in glioblastoma. AJNR Am J Neuroradiol 36:672–677CrossRefPubMed Qiao XJ, Ellingson BM, Kim HJ et al (2015) Arterial spin-labeling perfusion MRI stratifies progression-free survival and correlates with epidermal growth factor receptor status in glioblastoma. AJNR Am J Neuroradiol 36:672–677CrossRefPubMed
26.
Zurück zum Zitat Tykocinski ES, Grant RA, Kapoor GS et al (2012) Use of magnetic perfusion-weighted imaging to determine epidermal growth factor receptor variant III expression in glioblastoma. Neuro Oncol 14:613–623CrossRefPubMedPubMedCentral Tykocinski ES, Grant RA, Kapoor GS et al (2012) Use of magnetic perfusion-weighted imaging to determine epidermal growth factor receptor variant III expression in glioblastoma. Neuro Oncol 14:613–623CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Apostolova I, Ego K, Steffen IG et al (2016) The asphericity of the metabolic tumour volume in NSCLC: correlation with histopathology and molecular markers. Eur J Nucl Med Mol Imaging. doi:10.1007/s00259-016-3452-z PubMed Apostolova I, Ego K, Steffen IG et al (2016) The asphericity of the metabolic tumour volume in NSCLC: correlation with histopathology and molecular markers. Eur J Nucl Med Mol Imaging. doi:10.​1007/​s00259-016-3452-z PubMed
28.
Zurück zum Zitat Lindberg OR, McKinney A, Engler JR et al (2016) GBM heterogeneity as a function of variable epidermal growth factor receptor variant III activity. Oncotarget. doi:10.18632/oncotarget.12600 Lindberg OR, McKinney A, Engler JR et al (2016) GBM heterogeneity as a function of variable epidermal growth factor receptor variant III activity. Oncotarget. doi:10.​18632/​oncotarget.​12600
29.
Zurück zum Zitat Hofer S, Lassman AB (2010) Molecular markers in gliomas: impact for the clinician. Target Oncol 5:201–210CrossRefPubMed Hofer S, Lassman AB (2010) Molecular markers in gliomas: impact for the clinician. Target Oncol 5:201–210CrossRefPubMed
30.
Zurück zum Zitat Hu X, Miao W, Zou Y, Zhang W, Zhang Y, Liu H (2013) Expression of p53, epidermal growth factor receptor, Ki-67 and O6-methylguanine-DNA methyltransferase in human gliomas. Oncol Lett 6:130–134PubMedPubMedCentral Hu X, Miao W, Zou Y, Zhang W, Zhang Y, Liu H (2013) Expression of p53, epidermal growth factor receptor, Ki-67 and O6-methylguanine-DNA methyltransferase in human gliomas. Oncol Lett 6:130–134PubMedPubMedCentral
Metadaten
Titel
MRI features can predict EGFR expression in lower grade gliomas: A voxel-based radiomic analysis
verfasst von
Yiming Li
Xing Liu
Kaibin Xu
Zenghui Qian
Kai Wang
Xing Fan
Shaowu Li
Yinyan Wang
Tao Jiang
Publikationsdatum
28.07.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
European Radiology / Ausgabe 1/2018
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-017-4964-z

Weitere Artikel der Ausgabe 1/2018

European Radiology 1/2018 Zur Ausgabe

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.